Fig. 4.

S100A7 immunoreactivity and prognosis in human breast carcinoma tissues. S100A7 immunoreactivity in (a) inflamed epidermis of skin tissue as a positive control, showing (b) positive (n = 47) and (c) negative cases (n = 103) in human breast cancer tissues. d Different expression patterns of S100A7 were detected between the invasive front of surrounding adipose tissues and the intratumoral area. Strong immunoreactivity was detected in carcinoma cells (e) at the invasive front compared with (f) the intratumoral area with weak immunoreactivity. Kaplan-Meier curve according to S100A7 status indicating (g) breast cancer-specific survival (BCS) rate and (h) relapse-free survival (RFS) rate for all the patients, as well as RFS rate of (i) premenopausal (S100A7⁺, n = 20; S100A7⁻, n = 32) and (j) postmenopausal (S100A7⁺, n = 11; S100A7⁻, n = 59) patients with estrogen receptor-positive (ER⁺) status. P values were determined by log-rank test